Genetron Holdings (GTH) Stock
Company Profile
Price: $4.03
Market Cap: $127.29M
Exchange: NASDAQ
CEO: Mr. Sizhen Wang
Sector: Healthcare
Industry: Medical - Diagnostics & Research
Employees: -0.00B
Headquarters: Beijing, None
Website: Genetron Holdings
Business Summary
Genetron Holdings Limited, a precision oncology company, engages in the cancer molecular profiling, and harnessing technologies in molecular biology and data science for cancer treatment. The company offers diagnosis and monitoring services, and early screening services through laboratory developed tests services. It also provides in-vitro diagnostic products, including 8-gene lung cancer assay, an IVD assay product to detect lung cancer; Genetron 3D biochip reading instrument; Genetron S5, a semiconductor-based NGS system, which detects the nucleotide through detecting the change in pH; Genetron Chef System; Genetron S2000 platform, a production-scale sequencer; and Onco PanScan, a genomic profiling service for various solid tumors. In addition, it offers IDH1 and TERT gene assays for glioma; thyroid basic assay for thyroid tumor; platelet-derived growth factor receptor alpha assay for GIST cancer; and HCCscan, a qPCR-based assay to detect hepatocellular carcinoma. Further, it provides development services in the areas of genomics research and clinical development in collaboration with biopharmaceutical companies worldwide. The company has a strategic partnership with JD Health to create solutions for full-cycle cancer management. Genetron Holdings Limited was founded in 2015 and is headquartered in Beijing, the People's Republic of China.
Genetron Holdings Chart
Genetron Holdings News
Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model
Patented directed graph model delivers immediate, low-risk visibility of your identities and access in days, not months GOLD COAST, Australia & SEATTLE–(BUSINESS WIRE)–Gathid (ASX: GTH) today announced the debut of its new approach to identity and access governance. Inspired by the power of gathered identities, the platform pinpoints identity and access anomalies with its patented … The post Gathid Sets New Identity and Access Governance Standard with Introduction of Patented Identity Model appe...
-
headlinesoftoday.com
2024-04-10
Genetron Health Announces Completion of Going Private
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger … The post Genetron Health Announces Completion of Going Private appeared first on Headlines of Toda...
-
headlinesoftoday.com
2024-03-30
Genetron Health Announces Completion of Going Private Transaction
BEIJING, March 28, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, Nasdaq: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today the completion of its merger (the “Merger”) with Genetron New Co Limited (“Merger Sub”), pursuant to the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Merger Sub. As a result of the Merger, the Company has become a wholly owned subsidiary of Parent and will cease to be a publicly traded company.
-
globenewswire.com
2024-03-28
Genetron Health Announces Shareholders' Approval of Merger Agreement
BEIJING, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that at an extraordinary general meeting of shareholders (the “EGM”) held today, the Company's shareholders voted in favor of, among other things, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), pursuant to which, Merger Sub will be merged with and into the Company with the Company continuing as the surviving company and becoming a wholly owned subsidiary of Parent (the “Merger”), the plan of merger (the “Plan of Merger”) required to be filed with the Registrar of Companies of the Cayman Islands, and the transactions contemplated thereby, including the Merger.
-
globenewswire.com
2024-02-21
Genetron Health to Hold Extraordinary General Meeting of Shareholders
BEIJING, Jan. 17, 2024 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has called an extraordinary general meeting of shareholders (the “EGM”), to be held at on February 21, 2024 at 9:00 a.m. (Beijing time) at 1/F, Building 11, Zone 1, No. 8 Life Science Parkway, Changping District, Beijing, People's Republic of China, to consider and vote on, among other matters, the proposal to authorize and approve the previously announced agreement and plan of merger, dated as of October 11, 2023 (the “Merger Agreement”), among the Company, New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), and the plan of merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”) and the transactions contemplated thereby, including the Merger (as defined below).
-
globenewswire.com
2024-01-17
Genetron stock rallies on CEO-led deal to go private
Genetron Holdings has announced it will go private through an acquisition by a group of investors led by its co-founder and CEO Sizhen Wang and CICC Healthcare Investment Fund which values the Chinese precision oncology platform at US$126 million. The company's US-listed American Depository Shares (ADSs) jumped 27% in early Thursday trading to $1.1950.
-
proactiveinvestors.com
2023-10-12
Genetron Health Enters into Definitive Merger Agreement for Going Private Transaction
BEIJING, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that it has entered into a definitive Agreement and Plan of Merger (the “Merger Agreement”) with New Genetron Holding Limited (“Parent”) and Genetron New Co Limited (“Merger Sub”), a wholly-owned subsidiary of Parent. Pursuant to the Merger Agreement and subject to the terms and conditions thereof, Merger Sub will merge with and into the Company, with the Company continuing as the surviving entity and becoming a wholly-owned subsidiary of Parent (the “Merger”), in a transaction implying an equity value of the Company of approximately US$126.0 million.
-
globenewswire.com
2023-10-11
Genetron Health Announces Receipt of Notification from
BEIJING, May 23, 2023 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced that it has received written notification from the staff of the Listing Qualifications […]...
-
headlinesoftoday.com
2023-05-23
Genetron Health Announces Receipt of a Preliminary
BEIJING, Aug. 22, 2022 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced today that its Board of Directors (the “Board”) has received a preliminary non-binding proposal […]...
-
headlinesoftoday.com
2022-08-22
Genetron Holdings Earnings
This section highlight's Genetron Holdings's earnings, including earnings call transcripts, earnings surprises, and key dates.
Genetron Holdings Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q1 | 2022 | 2022-06-02 | N/A | N/A |
Genetron Holdings Earnings Dates
When is the next earnings date for GTH?
Date:Status: Unconfirmed
Time of Day:
Estimated EPS: $-
When was the last earnings date for GTH?
Date: 2024-05-10Fiscal Date Ending: 2024-03-30
EPS: $-
Estimated EPS: $-
Revenue: $-
Estimated Revenue: $-
Financial Statements
This section provides financial statements for Genetron Holdingsincluding income statements, balance sheets, and cash flow statements, both annually and quarterly.
Annual Income Statement
| Breakdown | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Revenue | $225.18M | $323.43M | $424.49M | $531.95M | $650.71M |
| Cost of Revenue | $132.45M | $178.44M | $164.27M | $193.98M | $369.28M |
| Gross Profit | $92.73M | $144.99M | $260.22M | $337.97M | $281.43M |
| Gross Profit Ratio | 41.18% | 44.83% | 61.30% | 63.53% | 43.25% |
| Research and Development Expenses | $71.41M | $91.70M | $149.00M | $253.95M | $290.29M |
| General and Administrative Expenses | $88.23M | $117.17M | $126.32M | $227.00M | $266.91M |
| Selling and Marketing Expenses | $182.47M | $253.56M | $246.96M | $343.16M | $364.56M |
| Selling General and Administrative Expenses | $270.71M | $370.73M | $373.28M | $570.16M | $631.47M |
| Other Expenses | $-233.63M | $-10.85M | $-8.53M | $-5.33M | $-8.71M |
| Operating Expenses | $332.19M | $451.58M | $513.75M | $818.78M | $913.05M |
| Cost and Expenses | $464.64M | $630.01M | $678.02M | $1.01B | $1.28B |
| Interest Income | $1.55M | $441.00K | $28.33M | $20.50M | $2.86M |
| Interest Expense | $- | $5.40M | $5.63M | $5.25M | $111.48M |
| Depreciation and Amortization | $27.86M | $-319.22M | $-2.80B | $20.50M | $85.39M |
| EBITDA | $-443.69M | $-625.81M | $-3.05B | $-460.31M | $-546.24M |
| EBITDA Ratio | -197.04% | -193.49% | -718.18% | -86.53% | -83.94% |
| Operating Income | $-232.98M | $-306.59M | $-253.53M | $-480.82M | $-631.62M |
| Operating Income Ratio | -103.46% | -94.79% | -59.73% | -90.39% | -97.07% |
| Total Other Income Expenses Net | $-227.08M | $-369.44M | $-2.82B | $-21.78M | $-179.01M |
| Income Before Tax | $-464.99M | $-676.03M | $-3.07B | $-502.60M | $-810.63M |
| Income Before Tax Ratio | -206.50% | -209.02% | -723.00% | -94.48% | -124.58% |
| Income Tax Expense | $-232.02M | $-354.54M | $-2.87B | $-64.19M | $73.26M |
| Net Income | $-464.99M | $-321.49M | $-198.10M | $-438.40M | $-883.89M |
| Net Income Ratio | -206.50% | -99.40% | -46.67% | -82.41% | -135.84% |
| EPS | $-6.73 | $-4.65 | $-3.29 | $-4.76 | $-9.53 |
| EPS Diluted | $-6.73 | $-4.65 | $-3.29 | $-4.76 | $-9.53 |
| Weighted Average Shares Outstanding | 69.07M | 69.07M | 60.28M | 92.11M | 92.80M |
| Weighted Average Shares Outstanding Diluted | 69.07M | 69.07M | 60.28M | 92.11M | 92.80M |
| SEC Filing | Source | Source | Source | Source | Source |
Quarterly Income Statement
| Breakdown | 2018-12-31 | 2019-03-31 | 2019-06-30 | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $73.98M | $66.65M | $72.49M | $81.34M | $102.94M | $76.84M | $101.73M | $111.96M | $133.94M | $92.06M | $140.49M | $152.54M | $146.86M | $110.32M | $137.75M | $201.32M | $201.32M |
| Cost of Revenue | $42.35M | $38.09M | $37.83M | $45.40M | $57.12M | $34.60M | $37.51M | $42.33M | $49.82M | $37.51M | $46.02M | $47.31M | $63.14M | $48.85M | $81.66M | $119.39M | $119.39M |
| Gross Profit | $31.63M | $28.57M | $34.66M | $35.95M | $45.82M | $42.24M | $64.22M | $69.63M | $84.12M | $54.55M | $94.46M | $105.23M | $83.72M | $61.47M | $56.09M | $81.93M | $81.93M |
| Gross Profit Ratio | 42.75% | 42.86% | 47.81% | 44.19% | 44.51% | 54.97% | 63.13% | 62.19% | 62.81% | 59.25% | 67.24% | 68.99% | 57.00% | 55.72% | 40.72% | 40.70% | 40.70% |
| Research and Development Expenses | $21.15M | $19.42M | $19.17M | $20.75M | $32.36M | $27.63M | $29.84M | $38.56M | $52.97M | $49.97M | $56.16M | $62.36M | $85.45M | $79.56M | $61.64M | $74.54M | $74.54M |
| General and Administrative Expenses | $30.92M | $27.21M | $27.85M | $33.42M | $28.70M | $21.62M | $27.91M | $32.44M | $44.35M | $44.60M | $54.58M | $62.98M | $64.84M | $50.24M | $60.14M | $78.27M | $78.27M |
| Selling and Marketing Expenses | $62.42M | $53.59M | $65.25M | $65.72M | $69.01M | $53.82M | $60.62M | $60.56M | $71.96M | $59.67M | $88.52M | $94.62M | $100.35M | $90.84M | $94.69M | $89.51M | $89.51M |
| Selling General and Administrative Expenses | $93.33M | $80.79M | $93.10M | $99.13M | $97.71M | $75.45M | $88.52M | $93.00M | $116.31M | $104.27M | $143.09M | $157.61M | $165.19M | $141.09M | $154.83M | $197.28M | $197.28M |
| Other Expenses | $-42.19M | $-60.19M | $-67.81M | $-187.96M | $-43.98M | $-44.78M | $-2.78B | $- | $2.40M | $- | $-8.08M | $-334.00K | $3.62M | $7.61M | $989.00K | $- | $- |
| Operating Expenses | $121.32M | $99.12M | $101.79M | $119.62M | $131.04M | $108.68M | $117.10M | $127.73M | $160.24M | $153.72M | $191.17M | $219.64M | $254.25M | $228.26M | $217.46M | $311.81M | $311.81M |
| Cost and Expenses | $163.68M | $137.21M | $139.62M | $165.02M | $188.16M | $143.28M | $154.61M | $170.07M | $210.06M | $191.23M | $237.19M | $266.94M | $317.40M | $277.11M | $299.12M | $431.19M | $431.19M |
| Interest Income | $624.00K | $328.00K | $84.00K | $26.00K | $3.00K | $30.00K | $198.00K | $12.77M | $17.27M | $105.00K | $9.45M | $482.00K | $18.79M | $5.90M | $541.00K | $30.10M | $30.10M |
| Interest Expense | $- | $401.00K | $1.07M | $2.13M | $1.80M | $1.22M | $827.00K | $1.56M | $1.63M | $6.14M | $1.41M | $5.79M | $229.00K | $906.00K | $66.60M | $- | $- |
| Depreciation and Amortization | $-48.38M | $-59.22M | $-67.97M | $-187.60M | $-50.74M | $-44.03M | $-2.78B | $13.88M | $30.01M | $9.94M | $9.77M | $1.66M | $21.37M | $5.90M | $541.00K | $27.08K | $54.88K |
| EBITDA | $-131.26M | $-130.43M | $-134.86M | $-271.61M | $-135.50M | $-111.19M | $-2.83B | $-45.33M | $-58.85M | $-99.06M | $-87.26M | $-113.92M | $-151.75M | $-160.89M | $-160.83M | $-166.75M | $-163.29M |
| EBITDA Ratio | -177.42% | -195.68% | -186.04% | -333.90% | -131.63% | -144.70% | -2782.98% | -40.49% | -43.93% | -107.61% | -62.12% | -74.68% | -103.33% | -145.84% | -116.75% | -82.83% | -81.11% |
| Operating Income | $-82.88M | $-71.21M | $-66.89M | $-84.01M | $-84.76M | $-67.16M | $-53.14M | $-59.21M | $-88.86M | $-109.00M | $-100.18M | $-124.84M | $-183.83M | $-166.79M | $-161.37M | $-175.97M | $-175.97M |
| Operating Income Ratio | -112.02% | -106.84% | -92.28% | -103.28% | -82.34% | -87.40% | -52.24% | -52.88% | -66.34% | -118.40% | -71.31% | -81.84% | -125.17% | -151.19% | -117.15% | -87.41% | -87.41% |
| Total Other Income Expenses Net | $-35.31M | $-60.84M | $-67.57M | $-188.29M | $-41.48M | $-47.83M | $-2.78B | $-1.11M | $-12.75M | $-9.83M | $-3.47M | $-10.44M | $-13.29M | $-8.11M | $-74.81M | $-23.81M | $-23.81M |
| Income Before Tax | $-124.38M | $-131.47M | $-135.69M | $-274.07M | $-134.80M | $-115.46M | $-2.83B | $-48.00M | $-73.22M | $-115.04M | $-92.15M | $-130.15M | $-165.27M | $-174.89M | $-236.18M | $-199.78M | $-199.78M |
| Income Before Tax Ratio | -168.12% | -197.26% | -187.18% | -336.93% | -130.95% | -150.25% | -2784.06% | -42.87% | -54.67% | -124.96% | -65.59% | -85.32% | -112.53% | -158.53% | -171.46% | -99.24% | -99.24% |
| Income Tax Expense | $6.19M | $-576.00K | $1.23M | $1.78M | $8.55M | $463.00K | $362.00K | $-12.32M | $-28.38M | $-3.79M | $-326.00K | $-1.17M | $-21.37M | $-6.42M | $-1.50M | $-371.00K | $-371.00K |
| Net Income | $-124.38M | $-131.47M | $-135.69M | $-274.07M | $-134.80M | $-115.46M | $-2.83B | $-48.00M | $-73.22M | $-115.04M | $-91.82M | $-128.97M | $-162.69M | $-168.47M | $-234.67M | $-199.41M | $-199.41M |
| Net Income Ratio | -168.12% | -197.26% | -187.18% | -336.93% | -130.95% | -150.25% | -2784.06% | -42.87% | -54.67% | -124.96% | -65.36% | -84.55% | -110.78% | -152.71% | -170.36% | -99.05% | -99.05% |
| EPS | $-1.80 | $-1.90 | $-1.96 | $-3.97 | $-1.95 | $-1.35 | $-85.22 | $-0.53 | $-0.83 | $-1.26 | $-1.00 | $-1.40 | $-1.76 | $-1.82 | $-2.53 | $-6.44 | $-6.44 |
| EPS Diluted | $-1.80 | $-1.90 | $-1.96 | $-3.97 | $-1.95 | $-1.35 | $-85.22 | $-0.53 | $-0.83 | $-1.26 | $-1.00 | $-1.40 | $-1.76 | $-1.82 | $-2.53 | $-6.44 | $-6.44 |
| Weighted Average Shares Outstanding | 69.07M | 69.07M | 69.07M | 69.07M | 69.07M | 85.36M | 33.24M | 90.85M | 88.36M | 91.62M | 91.98M | 92.27M | 92.56M | 92.57M | 92.72M | 30.98M | 30.98M |
| Weighted Average Shares Outstanding Diluted | 69.07M | 69.07M | 69.07M | 69.07M | 69.07M | 85.36M | 33.24M | 90.85M | 88.36M | 91.62M | 91.98M | 92.27M | 92.56M | 92.57M | 92.72M | 30.98M | 30.98M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $62.13M | $139.95M | $1.38B | $639.04M | $176.27M |
| Short Term Investments | $38.60M | $122.22M | $140.29M | $151.44M | $157.43M |
| Cash and Short Term Investments | $100.72M | $262.18M | $1.52B | $790.49M | $333.69M |
| Net Receivables | $70.86M | $105.37M | $208.34M | $388.38M | $323.36M |
| Inventory | $21.61M | $17.90M | $24.97M | $35.60M | $42.43M |
| Other Current Assets | $37.49M | $43.71M | $36.50M | $30.70M | $9.47M |
| Total Current Assets | $230.69M | $429.15M | $1.79B | $1.25B | $708.95M |
| Property Plant Equipment Net | $82.55M | $126.19M | $136.60M | $162.36M | $177.64M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $3.40M | $5.48M | $12.27M | $20.70M | $32.07M |
| Goodwill and Intangible Assets | $3.40M | $5.48M | $12.27M | $20.70M | $32.07M |
| Long Term Investments | $- | $- | $19.61M | $49.78M | $50.50M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $7.80M | $12.68M | $15.36M | $37.61M | $6.17M |
| Total Non-Current Assets | $93.75M | $144.36M | $183.83M | $270.44M | $266.37M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $324.44M | $573.51M | $1.97B | $1.52B | $975.33M |
| Account Payables | $11.90M | $49.95M | $34.07M | $55.77M | $63.05M |
| Short Term Debt | $929.00K | $34.88M | $75.17M | $40.13M | $131.22M |
| Tax Payables | $929.00K | $4.63M | $1.67M | $2.58M | $3.04M |
| Deferred Revenue | $8.87M | $18.19M | $8.42M | $11.96M | $22.04M |
| Other Current Liabilities | $46.08M | $109.72M | $111.19M | $157.24M | $173.56M |
| Total Current Liabilities | $67.77M | $212.74M | $228.84M | $265.09M | $389.87M |
| Long Term Debt | $- | $32.77M | $48.51M | $33.87M | $27.34M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.32B | $2.11B | $- | $8.61M | $9.76M |
| Total Non-Current Liabilities | $1.32B | $2.14B | $48.51M | $42.48M | $37.10M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $1.39B | $2.35B | $277.35M | $307.57M | $426.97M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $- | $17.00K | $59.00K | $61.00K | $61.00K |
| Retained Earnings | $-1.17B | $-1.84B | $-4.94B | $-5.44B | $-6.25B |
| Accumulated Other Comprehensive Income Loss | $112.26M | $69.21M | $-24.70M | $-69.09M | $56.17M |
| Other Total Stockholders Equity | $-8.36M | $-3.58M | $6.66B | $6.71B | $6.73B |
| Total Stockholders Equity | $-1.06B | $-1.78B | $1.69B | $1.21B | $546.12M |
| Total Equity | $-1.06B | $-1.78B | $1.69B | $1.21B | $548.36M |
| Total Liabilities and Stockholders Equity | $324.44M | $573.51M | $1.97B | $1.52B | $975.33M |
| Minority Interest | $- | $- | $- | $4.46M | $2.23M |
| Total Liabilities and Total Equity | $324.44M | $573.51M | $1.97B | $1.52B | $975.33M |
| Total Investments | $38.60M | $122.22M | $159.90M | $201.22M | $207.92M |
| Total Debt | $- | $67.64M | $123.68M | $73.99M | $158.57M |
| Net Debt | $-62.13M | $-72.31M | $-1.25B | $-565.05M | $-17.70M |
Quarterly Balance Sheet
| Breakdown | 2018-12-31 | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2020-12-31 | 2021-03-31 | 2021-06-30 | 2021-09-30 | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $62.13M | $5.39M | $139.95M | $180.89M | $1.84B | $1.64B | $1.38B | $1.07B | $1.07B | $815.14M | $639.04M | $319.29M | $327.55M | $176.27M | $176.27M |
| Short Term Investments | $38.60M | $- | $122.22M | $103.02M | $47.72M | $233.53M | $140.29M | $318.61M | $142.19M | $187.40M | $151.44M | $239.82M | $145.13M | $5.17M | $5.17M |
| Cash and Short Term Investments | $100.72M | $5.39M | $262.18M | $283.91M | $1.89B | $1.87B | $1.52B | $1.39B | $1.21B | $1.00B | $790.49M | $559.11M | $472.68M | $338.86M | $338.86M |
| Net Receivables | $70.86M | $85.62M | $105.37M | $114.77M | $115.20M | $162.79M | $208.34M | $224.10M | $261.15M | $365.58M | $388.38M | $406.56M | $432.18M | $257.93M | $257.93M |
| Inventory | $21.61M | $18.17M | $17.90M | $24.66M | $18.19M | $22.97M | $24.97M | $25.96M | $32.98M | $41.66M | $35.60M | $42.99M | $55.02M | $82.73M | $82.73M |
| Other Current Assets | $37.49M | $42.78M | $43.71M | $43.82M | $39.70M | $40.49M | $36.50M | $33.88M | $31.25M | $26.51M | $30.70M | $35.76M | $29.89M | $186.86M | $186.86M |
| Total Current Assets | $230.69M | $151.97M | $429.15M | $467.15M | $2.06B | $2.09B | $1.79B | $1.68B | $1.54B | $1.44B | $1.25B | $1.04B | $989.76M | $708.95M | $708.95M |
| Property Plant Equipment Net | $82.55M | $127.02M | $126.19M | $118.15M | $112.54M | $130.70M | $136.60M | $134.26M | $132.33M | $136.38M | $162.36M | $179.62M | $205.05M | $177.64M | $177.64M |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $3.40M | $3.69M | $5.48M | $5.61M | $6.60M | $9.45M | $12.27M | $13.73M | $15.28M | $- | $20.70M | $- | $27.89M | $32.07M | $32.07M |
| Goodwill and Intangible Assets | $3.40M | $3.69M | $5.48M | $5.61M | $6.60M | $9.45M | $12.27M | $13.73M | $15.28M | $15.10M | $20.70M | $24.78M | $27.89M | $32.07M | $32.07M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $19.61M | $33.18M | $36.33M | $37.01M | $49.78M | $48.72M | $49.20M | $50.50M | $50.50M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-15.10M | $-20.70M | $- | $- | $- | $- |
| Other Non-Current Assets | $7.80M | $10.85M | $12.68M | $14.45M | $9.84M | $11.97M | $15.36M | $26.25M | $23.42M | $38.87M | $58.30M | $31.10M | $31.46M | $-260.20M | $-260.20M |
| Total Non-Current Assets | $93.75M | $141.56M | $144.36M | $138.21M | $128.98M | $152.13M | $183.83M | $207.42M | $207.37M | $212.25M | $270.44M | $284.22M | $313.60M | $260.20M | $260.20M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.17M | $6.17M |
| Total Assets | $324.44M | $293.52M | $573.51M | $605.36M | $2.19B | $2.25B | $1.97B | $1.88B | $1.75B | $1.65B | $1.52B | $1.33B | $1.30B | $975.33M | $975.33M |
| Account Payables | $11.90M | $22.41M | $49.95M | $61.83M | $37.94M | $26.59M | $34.07M | $28.45M | $36.17M | $38.91M | $55.77M | $57.42M | $53.69M | $63.05M | $63.05M |
| Short Term Debt | $- | $34.58M | $34.88M | $77.23M | $67.36M | $68.56M | $75.17M | $47.42M | $46.99M | $47.23M | $40.13M | $53.05M | $111.94M | $- | $- |
| Tax Payables | $929.00K | $- | $4.63M | $- | $- | $- | $1.67M | $- | $- | $- | $2.58M | $- | $- | $- | $- |
| Deferred Revenue | $8.87M | $12.59M | $18.19M | $12.85M | $5.62M | $6.13M | $8.42M | $11.40M | $9.72M | $12.64M | $11.96M | $8.69M | $26.00M | $- | $- |
| Other Current Liabilities | $47.01M | $239.53M | $219.43M | $179.04M | $202.63M | $527.15M | $222.38M | $140.79M | $112.47M | $121.45M | $157.24M | $130.35M | $158.48M | $326.82M | $326.82M |
| Total Current Liabilities | $67.77M | $189.35M | $212.74M | $241.43M | $212.24M | $364.86M | $228.84M | $228.06M | $205.35M | $220.23M | $265.09M | $249.52M | $350.10M | $389.87M | $389.87M |
| Long Term Debt | $- | $39.30M | $32.77M | $27.81M | $25.36M | $46.01M | $48.51M | $45.71M | $40.34M | $32.69M | $33.87M | $30.13M | $49.16M | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.32B | $1.64B | $2.11B | $- | $- | $- | $- | $7.80M | $8.10M | $8.35M | $8.61M | $8.89M | $9.18M | $- | $- |
| Total Non-Current Liabilities | $1.32B | $1.68B | $2.14B | $27.81M | $25.36M | $46.01M | $48.51M | $53.51M | $48.43M | $41.05M | $42.48M | $39.03M | $58.34M | $- | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $27.34M | $27.34M |
| Total Liabilities | $1.39B | $1.87B | $2.35B | $269.24M | $237.60M | $410.87M | $277.35M | $281.57M | $253.79M | $261.28M | $307.57M | $288.54M | $408.44M | $426.97M | $426.97M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $- | $- | $17.00K | $48.00K | $59.00K | $59.00K | $59.00K | $59.00K | $59.00K | $60.00K | $61.00K | $61.00K | $61.00K | $61.00K | $61.00K |
| Retained Earnings | $-1.17B | $-1.71B | $-1.84B | $-1.96B | $-4.79B | $-4.84B | $-4.94B | $-5.05B | $-5.14B | $-5.27B | $-5.44B | $-5.61B | $-5.85B | $-6.25B | $-6.25B |
| Accumulated Other Comprehensive Income Loss | $112.26M | $134.60M | $69.21M | $77.30M | $92.28M | $18.23M | $-24.70M | $-21.14M | $-49.92M | $-44.78M | $-69.09M | $-64.34M | $20.73M | $- | $- |
| Other Total Stockholders Equity | $-8.36M | $-4.18M | $-3.58M | $2.22B | $6.66B | $6.66B | $6.66B | $6.67B | $6.68B | $6.70B | $6.71B | $6.71B | $6.72B | $6.79B | $6.79B |
| Total Stockholders Equity | $-1.06B | $-1.58B | $-1.78B | $336.12M | $1.96B | $1.84B | $1.69B | $1.59B | $1.49B | $1.38B | $1.21B | $1.04B | $891.95M | $546.12M | $546.12M |
| Total Equity | $-1.06B | $-1.58B | $-1.78B | $336.12M | $1.96B | $1.84B | $1.69B | $1.60B | $1.49B | $1.39B | $1.21B | $1.04B | $894.92M | $548.36M | $548.36M |
| Total Liabilities and Stockholders Equity | $324.44M | $293.52M | $573.51M | $605.36M | $2.19B | $2.25B | $1.97B | $1.88B | $1.75B | $1.65B | $1.52B | $1.33B | $1.30B | $975.33M | $975.33M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $8.54M | $8.21M | $7.04M | $4.46M | $3.94M | $2.98M | $2.23M | $2.23M |
| Total Liabilities and Total Equity | $324.44M | $293.52M | $573.51M | $605.36M | $2.19B | $2.25B | $1.97B | $1.88B | $1.75B | $1.65B | $1.52B | $1.33B | $1.30B | $975.33M | $975.33M |
| Total Investments | $38.60M | $- | $122.22M | $103.02M | $47.72M | $233.53M | $159.90M | $351.79M | $178.53M | $224.40M | $201.22M | $288.53M | $194.33M | $55.67M | $55.67M |
| Total Debt | $- | $73.88M | $67.64M | $105.04M | $92.72M | $114.57M | $123.68M | $93.13M | $87.33M | $79.93M | $73.99M | $83.19M | $161.10M | $- | $- |
| Net Debt | $-62.13M | $68.49M | $-72.31M | $-75.84M | $-1.75B | $-1.52B | $-1.25B | $-975.87M | $-979.49M | $-735.21M | $-565.05M | $-236.11M | $-166.45M | $-176.27M | $-176.27M |
Annual Cash Flow Statement
| Breakdown | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Net Income | $-464.99M | $-676.03M | $-3.07B | $-502.60M | $-810.63M |
| Depreciation and Amortization | $27.86M | $46.59M | $53.20M | $63.09M | $77.42M |
| Deferred Income Tax | $-6.49M | $360.22M | $2.83B | $31.33M | $- |
| Stock Based Compensation | $29.64M | $35.88M | $29.95M | $54.14M | $17.49M |
| Change in Working Capital | $-20.60M | $26.96M | $-124.57M | $-151.67M | $73.89M |
| Accounts Receivables | $-27.41M | $-48.15M | $-95.72M | $-153.94M | $-10.57M |
| Inventory | $-8.85M | $3.72M | $-7.08M | $-10.63M | $-6.82M |
| Accounts Payables | $2.94M | $26.63M | $-9.07M | $23.58M | $13.73M |
| Other Working Capital | $12.72M | $44.76M | $-12.71M | $-10.67M | $77.56M |
| Other Non Cash Items | $233.56M | $9.42M | $-24.79M | $-18.43M | $181.62M |
| Net Cash Provided by Operating Activities | $-201.02M | $-196.96M | $-300.90M | $-524.14M | $-460.20M |
| Investments in Property Plant and Equipment | $-47.42M | $-25.58M | $-50.03M | $-85.89M | $-82.14M |
| Acquisitions Net | $3.52M | $679.00K | $-13.37M | $2.00M | $- |
| Purchases of Investments | $-895.14M | $-479.10M | $-1.73B | $-2.10B | $-1.24B |
| Sales Maturities of Investments | $1.12B | $396.42M | $1.70B | $2.06B | $1.24B |
| Other Investing Activities | $-6.07M | $10.78M | $13.08M | $-10.57M | $3.00M |
| Net Cash Used for Investing Activities | $171.49M | $-96.81M | $-84.65M | $-136.28M | $-87.83M |
| Debt Repayment | $- | $-57.08M | $-40.28M | $-90.81M | $-54.92M |
| Common Stock Issued | $- | $18.00K | $1.68B | $- | $- |
| Common Stock Repurchased | $- | $-54.48M | $-4.10M | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $49.40M | $545.84M | $168.35M | $32.41M | $126.29M |
| Net Cash Used Provided by Financing Activities | $49.40M | $371.73M | $1.74B | $-58.41M | $71.37M |
| Effect of Forex Changes on Cash | $223.00K | $-139.00K | $-123.15M | $-17.90M | $13.89M |
| Net Change in Cash | $20.10M | $77.83M | $1.24B | $-736.72M | $-462.78M |
| Cash at End of Period | $62.13M | $139.95M | $1.38B | $639.04M | $176.27M |
| Cash at Beginning of Period | $42.03M | $62.13M | $139.95M | $1.38B | $639.04M |
| Operating Cash Flow | $-201.02M | $-196.96M | $-300.90M | $-524.14M | $-460.20M |
| Capital Expenditure | $-47.42M | $-25.58M | $-50.03M | $-85.89M | $-82.14M |
| Free Cash Flow | $-248.44M | $-222.54M | $-350.92M | $-610.04M | $-542.34M |
Quarterly Cash Flow Statement
| Breakdown | 2018-12-31 | 2019-03-31 | 2019-09-30 | 2019-12-31 | 2020-03-31 | 2020-06-30 | 2020-09-30 | 2021-12-31 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $- | $- | $-274.07M | $- | $- | $-2.83B | $-48.00M | $3.00B | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Income Tax | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Change in Working Capital | $- | $- | $-129.18M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Working Capital | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non Cash Items | $- | $- | $274.07M | $- | $- | $2.83B | $48.00M | $-3.45B | $- | $- | $- | $- | $- |
| Net Cash Provided by Operating Activities | $-35.77M | $-59.15M | $-129.18M | $-67.78M | $-71.53M | $- | $- | $-452.61M | $- | $- | $- | $- | $- |
| Investments in Property Plant and Equipment | $-11.03M | $-3.18M | $-17.42M | $-8.17M | $-5.55M | $- | $- | $-67.94M | $- | $- | $- | $- | $- |
| Acquisitions Net | $-3.31M | $707.00K | $- | $-37.00K | $1.80M | $- | $- | $-1.80M | $- | $- | $- | $- | $- |
| Purchases of Investments | $-99.28M | $-164.70M | $- | $-222.25M | $-251.91M | $- | $- | $223.02M | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $168.73M | $154.29M | $- | $100.26M | $265.75M | $- | $- | $-265.75M | $- | $- | $- | $- | $- |
| Other Investing Activities | $2.69M | $-4.29M | $39.84M | $10.97M | $-1.80M | $- | $- | $-32.09M | $- | $- | $- | $- | $- |
| Net Cash Used for Investing Activities | $64.42M | $-17.54M | $22.42M | $-119.23M | $8.29M | $- | $- | $-144.56M | $- | $- | $- | $- | $- |
| Debt Repayment | $- | $-3.00M | $- | $-42.07M | $-4.57M | $- | $- | $-4.57M | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $- | $21.54M | $50.04M | $363.76M | $108.34M | $- | $- | $-157.60M | $- | $- | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $- | $18.54M | $50.04M | $321.69M | $103.77M | $- | $- | $-162.18M | $- | $- | $- | $- | $- |
| Effect of Forex Changes on Cash | $92.00K | $12.00K | $-16.00K | $-123.00K | $405.00K | $- | $- | $-405.00K | $- | $- | $- | $- | $- |
| Net Change in Cash | $28.74M | $-58.14M | $-56.74M | $134.57M | $40.93M | $- | $- | $-759.76M | $- | $- | $- | $- | $- |
| Cash at End of Period | $62.13M | $3.98M | $-56.74M | $139.95M | $180.89M | $- | $- | $639.04M | $48.93M | $- | $- | $- | $- |
| Cash at Beginning of Period | $33.38M | $62.13M | $- | $5.39M | $139.95M | $- | $- | $1.40B | $48.93M | $- | $- | $- | $- |
| Operating Cash Flow | $-35.77M | $-59.15M | $-129.18M | $-67.78M | $-71.53M | $- | $- | $-452.61M | $- | $- | $- | $- | $- |
| Capital Expenditure | $-11.03M | $-3.18M | $-17.42M | $-8.17M | $-5.55M | $- | $- | $-67.94M | $- | $- | $- | $- | $- |
| Free Cash Flow | $-46.80M | $-62.34M | $-146.60M | $-75.94M | $-77.08M | $- | $- | $-520.55M | $- | $- | $- | $- | $- |
Genetron Holdings Dividends
Understand Genetron Holdings's dividend history, dividend yield, payout ratio, and more.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
5.60x
Genetron Holdings Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|
Valuation
Analyze the market cap, enterprise value, and valuation metrics for Genetron Holdings.
Market Cap & Enterprise Value
Market Cap: $127.29M
Enterprise Value: $2.13B
Valuation Ratios
P/E Ratio: -2.43
P/B Ratio: 3.94
P/CF Ratio: -4.67
Valuation Multiples
E/V to Sales: 3.28
E/V to EBITDA: -3.90
Market Cap & Enterprise Value
Market capitalization and enterprise value provide an understanding of a company's market value and total value, respectively.
- Market Cap: The total market value of a company's outstanding shares of stock. It represents the company's equity value and is calculated by multiplying the current share price by the total number of outstanding shares.
- Enterprise Value (EV): A measure of a company's total value, often seen as a more comprehensive alternative to equity market capitalization. It includes market cap plus debt, minority interest, and preferred shares, minus total cash and cash equivalents.
Valuation Ratios
Valuation ratios are used to evaluate the value of a company compared to its earnings, book value, and cash flow.
- P/E Ratio: Price to Earnings Ratio, indicating how much investors are willing to pay for a dollar of earnings.
- P/B Ratio: Price to Book Ratio, comparing the company's market value to its book value. A lower ratio may indicate undervaluation.
- P/CF Ratio: Price to Cash Flow Ratio, evaluating the market value relative to the operating cash flow. A lower ratio can signal a more attractive investment.
Valuation Multiples
Valuation multiples help assess a company's value relative to its revenue and earnings.
- EV to Sales: Enterprise Value to Sales, comparing the enterprise value to sales revenue. A lower ratio can indicate a more attractive investment.
- EV to EBITDA: Enterprise Value to EBITDA, comparing the enterprise value to earnings before interest, taxes, depreciation, and amortization. A lower ratio suggests a company may be undervalued.
Genetron Holdings Growth
View income_statement_chart2_annual_data financial growth metrics for Genetron Holdings, including income statement, balance sheet, and cash flow growth.
Income Growth
Revenue Growth: 0.00%
Operating Income Growth: 0.00%
Cash Flow Growth
Net Income Growth: 0.00%
Free Cash Flow Growth: 0.00%
Balance Sheet Growth
Total Assets Growth: 0.00%
Total Liabilities Growth: 0.00%
Income Growth
This section highlights key metrics related to income growth, showing how the company’s revenue and operating income have changed over time:
- Revenue Growth: The increase in a company's sales over time. It is a measure of how quickly the company is growing its revenue. This chart shows the historical trend of revenue growth.
- Operating Income Growth: The growth rate of a company's operating income, which is the income earned from its normal business operations. This chart helps to assess the company's operational efficiency and profitability growth over time.
Cash Flow Growth
This section highlights key metrics on the company's cash flow growth, reflecting changes in net income and free cash flow over time.
- Net Income Growth: The increase in a company's net profit over time. It reflects the company's ability to increase its profitability. This chart provides insight into how the company's bottom line has grown.
- Free Cash Flow Growth: The growth in a company's free cash flow, which is the cash generated by the company after accounting for capital expenditures. This chart is important for understanding the company's financial flexibility and ability to fund operations and growth.
Balance Sheet Growth
This section highlight key metrics related to balance sheet growth, which indicate how the company’s total assets and liabilities have changed over time:
- Total Assets Growth: The rate at which a company's total assets are increasing over time. This chart indicates how the company's asset base is expanding, which can be a sign of growth and investment in future operations.
- Total Liabilities Growth: The rate at which a company's total liabilities are increasing over time. This chart helps to assess the company's financial leverage and risk over time.
Peers: Medical - Diagnostics & Research
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
Psychemedics Corporation
PMD
|
$13.45M | $2.31 | $-0.72 | $-4.09 | $2.55 |
Sera Prognostics, Inc.
SERA
|
$233.61M | $7.21 | $-1.16 | $-5.15 | $2.66 |
Olink Holding AB (publ)
OLK
|
$3.24B | $26.08 | $-0.26 | $-98.51 | $6.20 |
DarioHealth Corp.
DRIO
|
$33.93M | $1.13 | $-1.93 | $-0.89 | $0.84 |
Biodesix, Inc.
BDSX
|
$245.35M | $1.69 | $-0.64 | $-2.90 | $32.99 |
Aclaris Therapeutics, Inc.
ACRS
|
$84.90M | $1.19 | $-1.27 | $-0.83 | $0.47 |
Castle Biosciences, Inc.
CSTL
|
$814.08M | $29.35 | $-2.14 | $-10.06 | $1.48 |
Prenetics Global Limited
PRE
|
$60.35M | $4.94 | $-5.58 | $-1.06 | $0.32 |
FONAR Corporation
FONR
|
$102.52M | $16.20 | $1.66 | $9.70 | $0.62 |
Exagen Inc.
XGN
|
$52.16M | $3.00 | $-1.34 | $-1.49 | $1.55 |
Sotera Health Company
SHC
|
$4.47B | $15.80 | $0.18 | $92.16 | $10.67 |
MDxHealth SA
MDXH
|
$94.58M | $2.00 | $-1.66 | $-2.37 | $14.16 |
Inotiv, Inc.
NOTV
|
$50.06M | $1.93 | $-4.10 | $-0.75 | $0.29 |
More metrics for Genetron Holdings
Access more key metrics, financials, ratios, and more with the links below.